Skip to main content

Table 1 Baseline characteristics for total cohort

From: A new paradigm evaluating cost per cure of HCV infection in the UK

  All patients (n = 154)
Age [Mean, (SD)] 49.6 (9.01)
Gender
 Male [%] 73.4 %
 Female [%] 26.6 %
Ethnicity
 White [%] 94.2 %
Liver disease (Metavir stage)
 Non-cirrhotic (F0-F3) [%] 78.6 %
 Cirrhotic (F4 including 1 HCC) [%] 21.4 %
Treatment history
 Experienced [%] 52.0 %
 Naïve [%] 48.0 %
Response to previous therapy  
 Relapse [%] 43.7 %
 No response [%] 45.0 %
 Missing [%] 11.3 %
HCV genotype
 Genotype 1a [%] 51.3 %
 Genotype 1b [%] 18.8 %
 G1 subtype Missing [%] 29.9 %
HCV therapy
 Telaprevir treatment [%] 69.1 %
 Boceprevir treatment [%] 33.1 %
IL28B status (SNP rs12979860)
 Heterozygous CT [%] 56.9 %
 Homozygous CC [%] 29.4 %
 Homozygous TT [%] 13.7 %
 Missing [%] 0.7 %
Comorbidities
 Depression [%] 26.0 %
 HIV co-infection [%] 6.5 %
 Diabetes [%] 5.2 %
 Haemophilia [%] 5.2 %
 Cancer [%] 3.9 %
 Renal failure [%] 0.7 %